Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy
Veronika Bachanová(University of Minnesota), Vaishalee P. Kenkre(University of Wisconsin–Madison), Sabarish Ayyappan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jaroslav Žák(Scripps Research Institute), Murali Janakiram(University of Minnesota), Daniel J. Weisdorf(University of Minnesota Medical Center), Joseph Maakaron(University of Minnesota), Qing Cao(University of Minnesota), Umar Farooq(Wake Forest University), Livia Hegerova(University of Washington)
Cited by 14
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
|PubMed|1999|651
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule
|Proceedings of the National Academy of Sciences|2012|594